# NOV - 1 2005

# 510K SUMMARY

This summary of ${ \pmb 5 } 1 { \pmb 0 } ( { \pmb k } )$ safety and effectiveness information is being submitted in accordance with the requirements of SMDA 1990 and 21 CFR 807.92

The assigned 510(k) number is: K05Z8/5

# COMPANY/CONTACT PERSON

Seradyn, Inc   
7998 Georgetown Road, Suite 1000   
Indianapolis, IN 46268

Establishment registration No: 1836010

Jack Rogers Manager of Regulatory Affairs Telephone: (317) 610-3823 Fax: (317) 610-0018

# DATE PREPARED

October 25, 2005

# DEVICE NAME

Trade Name: QMS® Amikacin Common Name: Homogeneous Particle-Enhanced Turbidimetric Immunoassay Device Classification: 21 CFR 862.3035; Amikacin Test System; Class II

# INTENDED USE

The QM® Amikacin assay is intended for the quantitative determination of amikacin in human serum or plasma on automated clinical chemistry analyzers.

Tu levels of amikacin to ensure appropriate therapy.

# LEGALLY MARKETED DEVICE TO WHICH EQUIVALENCY IS CLAIMED

Abbott TDx/TDxFLx Amikacin (K802669)

# DESCRIPTION OF DEVICE

The $\mathsf { Q M S } ^ { \otimes }$ Amkaiass ssteoussliziparcgltinatio and is based on the competitive binding principle.

In partcle agglutination assays, thedegreeof agglutination is inversely proportional to the quantiy drg n the reacion wellHence i o dru is present in the sample, the antiodis n the Amikacin Antibody Reagent (R1) will bind only to the bound drug on the particle which will cause it to agglutinate and will result in higher absorbance.If increased amount of competing drug is present in the sample, ths will result in decreased binding of bound drug by the antibody, esulting i a relative decrease in particle agglutination.This in turn results in lower absorbance.

The precise relationship between particle agglutination and concentration of the unlabeled drug in the sample is established by measuring the absorbance values of calibrators with known concentration of the drug.The absorbance of unknown samples can be interpolated from the absorbance values of the calibration curve and the concentration of the drug present in the sample can be calculated.

The assay consists of reagents R1: anti-amikacin monoclonal antibody and R2: amikacin-coated microparticles. A six-level set $Q M S ^ { \otimes }$   
assay.

# COMPARISON OF TECHNOLOGICAL CHARACTERISTICS

<table><tr><td rowspan=1 colspan=1>DeviceSeradyn QMS® Amikacin</td><td rowspan=1 colspan=1>PredicateAbbott TDx/TDxFLx Amikacin</td></tr><tr><td rowspan=1 colspan=1>Intended Use</td><td rowspan=1 colspan=1>The QMS Amikacin assay is for thequantitative determination of amikacinin human serum or plasma onautomated clinical chemistryanalyzers</td><td rowspan=1 colspan=1>The TDx/TDxFLx Amikacin assay isa reagent system for thequantitative measurement ofamikacin, an aminoglycosideantibiotic drug, in serum or plasma.</td></tr><tr><td rowspan=1 colspan=1>Indicationsfor Use</td><td rowspan=1 colspan=1>The results obtained are used in thediagnosis and treatment of amikacinoverdose and in monitoring levels ofamikacin to ensure appropriatetherapy.</td><td rowspan=1 colspan=1>The measurements obtained areused in the diagnosis and treatmentof amikacin overdose and inmonitoring levels of amikacin toensure appropriate therapy.</td></tr><tr><td rowspan=1 colspan=1>Methodology</td><td rowspan=1 colspan=1>Homogeneous particle-enhancedturbidimetric immunoassay (particleagglutination)</td><td rowspan=1 colspan=1>Fluorescence PolarizationImmunoassay (FPIA) technology.</td></tr><tr><td rowspan=1 colspan=1>ReagentComponents</td><td rowspan=1 colspan=1>Two (2) reagent system:Anti-amikacin Antibody Reagent(R1) in buffers containingstabilizers with sodium azideAmikacin-coated MicroparticleReagent (R2) in buffer containingstabilizers with sodium azide</td><td rowspan=1 colspan=1>Three (3) reagent system:Pretreatment Solution (P)Surfactant in buffer containingprotein stabilizer and sodiumazide.S Amikacin Antiserum (Sheep) inbuffer with protein stabilizer andSodium azide.T Amikacin Fluorescein Tracer inbuffer with protein stabilizer,surfactant and Sodium azide</td></tr><tr><td rowspan=1 colspan=1>Calibration</td><td rowspan=1 colspan=1>QMS AmikacinCalibrators - six levels</td><td rowspan=1 colspan=1>Amikacin Calibrators - six levels</td></tr></table>

# SUMMARY OF CLINICAL TESTING

# Accuracy

Accuracy by Recovery was determined by spiking USP traceable amikacin into human serum negative for the drug to achieve concentrations of 18.4 and $9 . 2 \mu g / m L$ The samples were analyzed in duplicate with the QMS Amikacin assay.

<table><tr><td rowspan=1 colspan=1>THEORETICALCONC.(μG/ML)</td><td rowspan=1 colspan=1>Rep 1</td><td rowspan=1 colspan=1>Rep 2</td><td rowspan=1 colspan=1>MeanRecoveredConc.</td><td rowspan=1 colspan=1>SD</td><td rowspan=1 colspan=1>CV</td><td rowspan=1 colspan=1>% RecoveryAcceptanceCriteria:100±10%</td></tr><tr><td rowspan=1 colspan=1>9.2</td><td rowspan=1 colspan=1>8.92</td><td rowspan=1 colspan=1>8.72</td><td rowspan=1 colspan=1>8.82</td><td rowspan=1 colspan=1>0.14</td><td rowspan=1 colspan=1>1.59%</td><td rowspan=1 colspan=1>95.87</td></tr><tr><td rowspan=1 colspan=1>18.4</td><td rowspan=1 colspan=1>16.79</td><td rowspan=1 colspan=1>17.13</td><td rowspan=1 colspan=1>16.96</td><td rowspan=1 colspan=1>0.17</td><td rowspan=1 colspan=1>1.00%</td><td rowspan=1 colspan=1>92.17</td></tr><tr><td rowspan=1 colspan=6>Mean Percent Recovery</td><td rowspan=1 colspan=1>94.02</td></tr></table>

# Linearity

Linearity by Dilution was determined by a study based on the NCCLS guideline EP6: Evaluation of the Linearity of Quantitative Measurement.

A linear regression analysis plot of USP Amikacin against recovered amikacin resulted in a line with a correlation coefficient $\{ R ^ { 2 } \}$ athahss

<table><tr><td rowspan=1 colspan=1>THEORETICALCONC.(μg/mL)</td><td rowspan=1 colspan=1>Rep 1</td><td rowspan=1 colspan=1>Rep 2</td><td rowspan=1 colspan=1>MeanRecoveredConc.</td><td rowspan=1 colspan=1>SD</td><td rowspan=1 colspan=1>CV</td><td rowspan=1 colspan=1>% Recovery</td></tr><tr><td rowspan=1 colspan=1>1.5</td><td rowspan=1 colspan=1>1.77</td><td rowspan=1 colspan=1>1.57</td><td rowspan=1 colspan=1>1.67</td><td rowspan=1 colspan=1>0.10</td><td rowspan=1 colspan=1>5.99</td><td rowspan=1 colspan=1>111. 33%</td></tr><tr><td rowspan=1 colspan=1>6.5</td><td rowspan=1 colspan=1>6.44</td><td rowspan=1 colspan=1>6.51</td><td rowspan=1 colspan=1>6.48</td><td rowspan=1 colspan=1>0.04</td><td rowspan=1 colspan=1>0.54</td><td rowspan=1 colspan=1>99.69%</td></tr><tr><td rowspan=1 colspan=1>15.0</td><td rowspan=1 colspan=1>14.84</td><td rowspan=1 colspan=1>14.49</td><td rowspan=1 colspan=1>14.67</td><td rowspan=1 colspan=1>0.18</td><td rowspan=1 colspan=1>1.19</td><td rowspan=1 colspan=1>97.80%</td></tr><tr><td rowspan=1 colspan=1>27.5</td><td rowspan=1 colspan=1>26.69</td><td rowspan=1 colspan=1>25.95</td><td rowspan=1 colspan=1>26.32</td><td rowspan=1 colspan=1>0.37</td><td rowspan=1 colspan=1>1.41</td><td rowspan=1 colspan=1>95.71%</td></tr><tr><td rowspan=1 colspan=1>42.5</td><td rowspan=1 colspan=1>41.24</td><td rowspan=1 colspan=1>41.63</td><td rowspan=1 colspan=1>41.44</td><td rowspan=1 colspan=1>0.20</td><td rowspan=1 colspan=1>0.47</td><td rowspan=1 colspan=1>97.51%</td></tr><tr><td rowspan=1 colspan=6>Mean Percent Recovery</td><td rowspan=1 colspan=1>100.41%</td></tr></table>

# Sensitivity

The Analytical Sensitivity or Least Detectable Dose (LDD) of the assay is defined as the concentration at which the lowest concentration is distinguishable from zero with $9 5 \%$ confidence.

The average LDD is $0 . 5 4 ~ \mu \ g / m L$ , supporting a claim of $0 . 8 \mu g / m L$

# Assay Range

Based on the Accuracy, Linearity, and Sensitivity (LDD) data, the package insert claim for the reportable range for the assay will be 1.5 to $5 0 \mu g / m L$ .

# Method Comparison

A sudy was conducted according to NCCL Guideline 9: Method Comparison and Bias Estimation Us  pls cpa ccuracyoveryiacassy Amikacin assay  Abot $x ^ { \otimes }$ Amikacin assay.

val  plot a o ia results, using Passing  Bablok parameters, are:

$N = 5 6$   
Slope $\mathbf { \Omega } = 1 . 0 0$ EMPY   
y-intercept $= 0 . 2 5$   
$R = 0 . 9 9 6$ EPY   
$\mathsf { R } ^ { 2 } = 0 . 9 9 2$ EY

Results show excellent correlation between the two assays.

# Precision

A precision study was performed usig the National Commitee or Clinical Laboratory Standards guideli valuation Precision erformance ClinicalChemisry Devis.   

<table><tr><td rowspan=1 colspan=3></td><td rowspan=1 colspan=2>Within Run</td><td rowspan=1 colspan=2>Between Day</td><td rowspan=1 colspan=2>Total</td></tr><tr><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1>N</td><td rowspan=1 colspan=1>Meanμg/mL</td><td rowspan=1 colspan=1>SD</td><td rowspan=1 colspan=1>CV (%)</td><td rowspan=1 colspan=1>SD</td><td rowspan=1 colspan=1>CV (%)</td><td rowspan=1 colspan=1>SD</td><td rowspan=1 colspan=1>CV (%)</td></tr><tr><td rowspan=1 colspan=1>Low Control</td><td rowspan=1 colspan=1>80</td><td rowspan=1 colspan=1>4.09</td><td rowspan=1 colspan=1>0.22</td><td rowspan=1 colspan=1>5.37</td><td rowspan=1 colspan=1>0.19</td><td rowspan=1 colspan=1>4.77</td><td rowspan=1 colspan=1>0.41</td><td rowspan=1 colspan=1>9.94</td></tr><tr><td rowspan=1 colspan=1>Mid Control</td><td rowspan=1 colspan=1>80</td><td rowspan=1 colspan=1>12.00</td><td rowspan=1 colspan=1>0.21</td><td rowspan=1 colspan=1>1.79</td><td rowspan=1 colspan=1>0.08</td><td rowspan=1 colspan=1>0.70</td><td rowspan=1 colspan=1>0.74</td><td rowspan=1 colspan=1>6.22</td></tr><tr><td rowspan=1 colspan=1>High Control</td><td rowspan=1 colspan=1>80</td><td rowspan=1 colspan=1>24.37</td><td rowspan=1 colspan=1>0.47</td><td rowspan=1 colspan=1>1.93</td><td rowspan=1 colspan=1>0.40</td><td rowspan=1 colspan=1>1.65</td><td rowspan=1 colspan=1>1.54</td><td rowspan=1 colspan=1>6.32</td></tr></table>

Acceptance Criteria: $\leq 1 0 \%$ total CV

# Specificity

There are no metabolites of amikacin.

# Interferences

Intference studes were conducted using NCCL GuidelieEP: InterferenceTestng inCnical Chemistry.

# Endogenous Substances

<table><tr><td rowspan=1 colspan=1>Interfering Substance</td><td rowspan=1 colspan=1>InterferentConcentration</td><td rowspan=1 colspan=1>N</td><td rowspan=1 colspan=1>Target(No Interferent)μg/mL</td><td rowspan=1 colspan=1>MeanRecoveryμg/mL</td><td rowspan=1 colspan=1>% RecoveryAcceptanceCriteria:100±10%</td></tr><tr><td rowspan=1 colspan=1>Bilirubin</td><td rowspan=1 colspan=1>15mg/dL</td><td rowspan=1 colspan=1>2</td><td rowspan=1 colspan=1>21.65</td><td rowspan=1 colspan=1>20.87</td><td rowspan=1 colspan=1>96.40</td></tr><tr><td rowspan=1 colspan=1>Hemoglobin</td><td rowspan=1 colspan=1>10g/L</td><td rowspan=1 colspan=1>2</td><td rowspan=1 colspan=1>17.32</td><td rowspan=1 colspan=1>16.18</td><td rowspan=1 colspan=1>93.42</td></tr><tr><td rowspan=1 colspan=1>Triglyceride</td><td rowspan=1 colspan=1>1691 mg/dL</td><td rowspan=1 colspan=1>3</td><td rowspan=1 colspan=1>24.03</td><td rowspan=1 colspan=1>23.14</td><td rowspan=1 colspan=1>96.30</td></tr><tr><td rowspan=1 colspan=1>Total Protein</td><td rowspan=1 colspan=1>12 g/dL</td><td rowspan=1 colspan=1>3</td><td rowspan=1 colspan=1>24.03</td><td rowspan=1 colspan=1>23.07</td><td rowspan=1 colspan=1>96.00</td></tr></table>

# HAMA

<table><tr><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1>Rep 1μg/mL</td><td rowspan=1 colspan=1>Rep 2μg/mL</td><td rowspan=1 colspan=1>MeanRecoveryμg/mL</td><td rowspan=1 colspan=1>SD</td><td rowspan=1 colspan=1>CV</td><td rowspan=1 colspan=1>% RecoveryAcceptance Criteria:100±10%</td></tr><tr><td rowspan=1 colspan=1>HAMAType-1</td><td rowspan=1 colspan=1>20.68</td><td rowspan=1 colspan=1>20.13</td><td rowspan=1 colspan=1>20.41</td><td rowspan=1 colspan=1>0.27</td><td rowspan=1 colspan=1>1.35</td><td rowspan=1 colspan=1>100.5</td></tr><tr><td rowspan=1 colspan=1>Control</td><td rowspan=1 colspan=1>20.29</td><td rowspan=1 colspan=1>20.33</td><td rowspan=1 colspan=1>20.31</td><td rowspan=1 colspan=1>0.02</td><td rowspan=1 colspan=1>0.10</td><td rowspan=1 colspan=1>100.0</td></tr><tr><td rowspan=1 colspan=1>HAMAType-2</td><td rowspan=1 colspan=1>16.97</td><td rowspan=1 colspan=1>16.99</td><td rowspan=1 colspan=1>16.98</td><td rowspan=1 colspan=1>0.01</td><td rowspan=1 colspan=1>0.05</td><td rowspan=1 colspan=1>98.04</td></tr><tr><td rowspan=1 colspan=1>Control</td><td rowspan=1 colspan=1>16.99</td><td rowspan=1 colspan=1>17.65</td><td rowspan=1 colspan=1>17.32</td><td rowspan=1 colspan=1>0.33</td><td rowspan=1 colspan=1>1.91</td><td rowspan=1 colspan=1>100.0</td></tr></table>

# Common Co-Administered Drugs

<table><tr><td rowspan=1 colspan=1>Cross-reactant Drug</td><td rowspan=1 colspan=1>Conc. Testedμg/mL</td><td rowspan=1 colspan=1>Percent Cross-Reactivity</td></tr><tr><td rowspan=1 colspan=1>5-Fluorocytosine</td><td rowspan=1 colspan=1>30</td><td rowspan=1 colspan=1>-0.39</td></tr><tr><td rowspan=1 colspan=1>Amphotericin</td><td rowspan=1 colspan=1>100</td><td rowspan=1 colspan=1>1.33</td></tr><tr><td rowspan=1 colspan=1>Ampicillin</td><td rowspan=1 colspan=1>50</td><td rowspan=1 colspan=1>ND</td></tr><tr><td rowspan=1 colspan=1>Carbenicillin</td><td rowspan=1 colspan=1>2500</td><td rowspan=1 colspan=1>ND</td></tr><tr><td rowspan=1 colspan=1>Cephalexin</td><td rowspan=1 colspan=1>320</td><td rowspan=1 colspan=1>ND</td></tr><tr><td rowspan=1 colspan=1>Cephalosporin C</td><td rowspan=1 colspan=1>1000</td><td rowspan=1 colspan=1>ND</td></tr><tr><td rowspan=1 colspan=1>Cephalothin</td><td rowspan=1 colspan=1>1000</td><td rowspan=1 colspan=1>ND</td></tr><tr><td rowspan=1 colspan=1>Chloramphenicol</td><td rowspan=1 colspan=1>250</td><td rowspan=1 colspan=1>0.55</td></tr><tr><td rowspan=1 colspan=1>Clindamycin</td><td rowspan=1 colspan=1>2000</td><td rowspan=1 colspan=1>ND</td></tr><tr><td rowspan=1 colspan=1>Erythromycin</td><td rowspan=1 colspan=1>500</td><td rowspan=1 colspan=1>ND</td></tr><tr><td rowspan=1 colspan=1>Ethacrynic acid</td><td rowspan=1 colspan=1>400</td><td rowspan=1 colspan=1>ND</td></tr><tr><td rowspan=1 colspan=1>Furosemide</td><td rowspan=1 colspan=1>100</td><td rowspan=1 colspan=1>1.00</td></tr><tr><td rowspan=1 colspan=1>Fusidic acid</td><td rowspan=1 colspan=1>1000</td><td rowspan=1 colspan=1>ND</td></tr><tr><td rowspan=1 colspan=1>Gentamicin</td><td rowspan=1 colspan=1>100</td><td rowspan=1 colspan=1>ND</td></tr><tr><td rowspan=1 colspan=1>Kanamycin A</td><td rowspan=1 colspan=1>400</td><td rowspan=1 colspan=1>ND</td></tr><tr><td rowspan=1 colspan=1>Kanamycin B</td><td rowspan=1 colspan=1>400</td><td rowspan=1 colspan=1>ND</td></tr><tr><td rowspan=1 colspan=1>Lincomycin</td><td rowspan=1 colspan=1>2000</td><td rowspan=1 colspan=1>ND</td></tr><tr><td rowspan=1 colspan=1>Methicillin</td><td rowspan=1 colspan=1>200</td><td rowspan=1 colspan=1>0.41</td></tr><tr><td rowspan=1 colspan=1>Methotrexate</td><td rowspan=1 colspan=1>500</td><td rowspan=1 colspan=1>ND</td></tr><tr><td rowspan=1 colspan=1>MethyIprednisolone</td><td rowspan=1 colspan=1>200</td><td rowspan=1 colspan=1>0.638</td></tr><tr><td rowspan=1 colspan=1>Neomycin</td><td rowspan=1 colspan=1>1000</td><td rowspan=1 colspan=1>ND</td></tr><tr><td rowspan=1 colspan=1>Netilmycin</td><td rowspan=1 colspan=1>125</td><td rowspan=1 colspan=1>ND</td></tr><tr><td rowspan=1 colspan=1>Oxytetracycline</td><td rowspan=1 colspan=1>2000</td><td rowspan=1 colspan=1>ND</td></tr><tr><td rowspan=1 colspan=1>Penicillin V</td><td rowspan=1 colspan=1>100</td><td rowspan=1 colspan=1>1.38</td></tr><tr><td rowspan=1 colspan=1>Prednisolone</td><td rowspan=1 colspan=1>12</td><td rowspan=1 colspan=1>2.36</td></tr><tr><td rowspan=1 colspan=1>Rifampicin</td><td rowspan=1 colspan=1>500</td><td rowspan=1 colspan=1>ND</td></tr><tr><td rowspan=1 colspan=1>Spectinomycin</td><td rowspan=1 colspan=1>100</td><td rowspan=1 colspan=1>ND</td></tr><tr><td rowspan=1 colspan=1>Streptomycin</td><td rowspan=1 colspan=1>400</td><td rowspan=1 colspan=1>ND</td></tr><tr><td rowspan=1 colspan=1>Sulfadiazine</td><td rowspan=1 colspan=1>100</td><td rowspan=1 colspan=1>ND</td></tr><tr><td rowspan=1 colspan=1>Sulfamethoxazole</td><td rowspan=1 colspan=1>400</td><td rowspan=1 colspan=1>ND</td></tr><tr><td rowspan=1 colspan=1>Tetracycline</td><td rowspan=1 colspan=1>2000</td><td rowspan=1 colspan=1>ND</td></tr><tr><td rowspan=1 colspan=1>Tobramycin</td><td rowspan=1 colspan=1>100</td><td rowspan=1 colspan=1>0.32</td></tr><tr><td rowspan=1 colspan=1>Trimethoprim</td><td rowspan=1 colspan=1>200</td><td rowspan=1 colspan=1>ND</td></tr><tr><td rowspan=1 colspan=1>Vancomycin</td><td rowspan=1 colspan=1>400</td><td rowspan=1 colspan=1>ND</td></tr></table>

\*ND Not Detected

# Anticoagulants

Studies were conducted to determine the performance characteristics of the assay for both serum and plasma samples containing amikacin.

The results indicate that there is no significant diference between the recovery of amikacin in serum or plasma. The collection tubes evaluated show no adverse effects on the recovery of amikacin, within the experimental error for the spiking study.

A claim for assay application to both serum and plasma samples is thus supported.

# On-Board Stability

# Calibration Curve stability

Calibration curve stability of a period of 28 days is supported by the data.

# Reagent On-Board Stability

A 40 day on-board reagent stability claim is supported by the data.

# CONCLUSION

As summarized above, the $\mathsf { Q M S } ^ { \otimes }$ Amikacin assay is substantially equivalent to the Abbott $T \Delta x ^ { \circledcirc } / T \Delta x F L x ^ { \circledcirc }$ Amikacin assay. Substantial equivalence has been demonstrated through performance testing to verify that the device functions as intended and that design specifications have been satisfied.

# NOV - 1 2005

Mr. Jack Rogers, MS, RAC Manger of Regulatory Affairs Seradyn, Inc.   
7998 Georgetown Road   
Suite 1000   
Indianapolis, IN 46268-5620

Re: k052815 Trade/Device Name: QMS® Amikacin Regulation Number: 21 CFR 862.3035 Regulation Name: Amikacin test system Regulatory Class: Class II Product Code: KLQ Dated: October 3, 2005 Received: October 4, 2005

Dear Mr. Rogers

We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration.

If your device is classified (see above) into either class II (Special Controls) or classIII (PMA), it may be subject to such additional controls. Existing major regulations affecting your device can be found in Title 21, Code of Federal Regulations (CFR), Parts 800 to 895. In addition, FDA may publish further announcements concerning your device in the Federal Register.

Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Parts 801 and 809); and good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820).

This letter will allow you to begin marketing your device as described in your Section 510(k) pmar otihedustlanc y devi aly marketed predicate device results in a classification or your device and thus, permits your device to proceed to the market.

If you desire specii information about the application o labeling requirements to your device, or questions on the promotion and advertising of your device, please contact the Office of In Vitro Diagnostic Device Evaluation and Safety at (240) 276-0484. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21CFR Part 807.97). You may obtain other general information on your responsibilities under the Act from the Division of Small Manufacturers, International and Consumer Assistance at its toll-free number (800) 638-2041 or (301) 443-6597 or at its Internet address   
http://www.fda.gov/cdrh/industry/support/index.html.

Sincerely yours,

![](images/3e3e54fc1204d294c03bf1dbcffcada41041e9b5b489c969589dd397a5acc7df.jpg)

Alberto Gutierez, Ph.D.   
Director   
Division of Chemistry and Toxicology   
Office of In Vitro Diagnostic Device Evaluation and Safety   
Center for Devices and Radiological Health

# Indications for Use

510k) Umbe. K052815

Device Name: QMS® Amikacin

# Indications for Use:

The QMS® Amikacin assay is intended for the quantitative determination of amikacin in human serum or plasma on automated clinical chemistry analyzers.

The results obtained are used in the diagnosis and treatment of amikacin overdose and in monitoring levels of amikacin to ensure appropriate therapy.

Concurrence of CDRH, Office of In Vitro Diagnostic Devices (OIVD)

Macy Pullips   
Division Sign-Off   
Office of In Vitro Diagnostic Device   
Evaluation and Safety   
510(k) K052815

Page 1 of